KalVista Pharmaceuticals, Inc. (KALV)

KalVista Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is May - April.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Cost of Revenue	71.71	86.17	80.28	70.17	41.29
Gross Profit	-71.71	-86.17	-80.28	-70.17	-41.29
Selling, General & Admin	116.29	54.28	30.6	26.45	16.64
Operating Expenses	116.29	54.28	30.6	26.45	16.64
Operating Income	-188	-140.45	-110.87	-96.61	-57.92
Interest Expense	-5.79	-	-	-	-
Interest & Investment Income	6.44	3.9	2.23	1.09	0.9
Currency Exchange Gain (Loss)	2.48	0.14	0.09	-1.54	0.85
Other Non Operating Income (Expenses)	3.25	8.44	15.78	15.3	9.93
EBT Excluding Unusual Items	-181.61	-127.97	-92.77	-81.76	-46.24
Gain (Loss) on Sale of Investments	1.56	1.33	-0.14	-0.58	-
Pretax Income	-180.05	-126.64	-92.91	-82.34	-46.24
Income Tax Expense	3.39	-	-	-	-
Net Income	-183.44	-126.64	-92.91	-82.34	-46.24
Net Income to Common	-183.44	-126.64	-92.91	-82.34	-46.24
Shares Outstanding (Basic)	50	37	28	24	19
Shares Outstanding (Diluted)	50	37	28	24	19
Shares Change (YoY)	34.98%	31.89%	13.96%	28.17%	7.58%
EPS (Basic)	-3.69	-3.44	-3.33	-3.36	-2.42
EPS (Diluted)	-3.69	-3.44	-3.33	-3.36	-2.42
Free Cash Flow	-153.34	-89.27	-76.46	-79.07	-30.25
Free Cash Flow Per Share	-3.09	-2.43	-2.74	-3.23	-1.58
EBITDA	-187.05	-139.63	-110.15	-96.05	-57.39
D&A For EBITDA	0.94	0.82	0.72	0.56	0.54
EBIT	-188	-140.45	-110.87	-96.61	-57.92

Updated Jul 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q